Of Mice and Men (and Dogs): development of a xenogeneic DNA vaccine for canine oral malignant melanoma
نویسندگان
چکیده
Philip J. Bergman*, Jedd D. Wolchok 1 Bright Heart Veterinary Centers Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center __________________________________________________________________________________ *Correspondence: Philip J. Bergman DVM, MS, PhD, Diplomate ACVIM-Oncology, Chief Medical Officer, Bright Heart Veterinary Centers, 80 Business Park Drive, Suite 110, USA; Tel: 914-219-5415 (office); Fax: 914-219-5417; e-mail: [email protected] Adjunct Associate Faculty Member, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021
منابع مشابه
A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma
A xenogeneic DNA vaccination has been licensed for use in dogs with locally controlled stage II and III oral malignant melanoma (OMM). At present, there are limited outcome data for dogs with OMM treated with surgery and immunotherapy. The aim of this study is to retrospectively review the outcome and survival of 32 dogs affected by OMM that were treated with a combination of surgery and the xe...
متن کاملPilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma
Spontaneous canine malignant melanoma provides an excellent pre-clinical model to study DNA vaccines for melanoma immunotherapy. A USDA-approved xenogeneic human tyrosinase (huTYR) plasmid DNA vaccine delivered intramuscularly induces detectable immune responses and has clinical activity in some dogs with melanoma. The objective of this pilot study was to evaluate the feasibility, safety and im...
متن کاملLong-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.
PURPOSE Canine malignant melanoma (CMM) is a spontaneous, aggressive, and metastatic neoplasm. Preclinical mouse studies have shown that xenogeneic DNA vaccination with genes encoding tyrosinase family members can induce antibody and cytotoxic T-cell responses, resulting in tumor rejection. These studies provided the rationale for a trial of xenogeneic DNA vaccination in CMM using the human tyr...
متن کاملCSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.
PURPOSE Due to the many similarities with its human counterpart, canine malignant melanoma (cMM) is a valuable model in which to assess the efficacy of novel therapeutic strategies. The model is herein used to evaluate the immunogenicity, safety, and therapeutic efficacy of a human chondroitin sulfate proteoglycan-4 (hCSPG4) DNA-based vaccine. The fact that homology between hCSPG4 and cCSPG4 am...
متن کاملAdvances in Brief Long-Term Survival of Dogs with Advanced Malignant Melanoma after DNA Vaccination with Xenogeneic Human Tyrosinase: A Phase I Trial
Purpose: Canine malignant melanoma (CMM) is a spontaneous, aggressive, and metastatic neoplasm. Preclinical mouse studies have shown that xenogeneic DNA vaccination with genes encoding tyrosinase family members can induce antibody and cytotoxic T-cell responses, resulting in tumor rejection. These studies provided the rationale for a trial of xenogeneic DNA vaccination in CMM using the human ty...
متن کامل